Imagine receiving a single medical treatment that could keep your cholesterol under control for decades, effectively eliminating the need for daily pills, routine prescription refills, and the constant psychological reminder of managing a chronic condition. Recent advances in gene editing are bringing that possibility tantalizingly close to medical reality. Yet, as researchers push the boundaries of modern science, medical experts are issuing a timely caution: the very technology that holds the potential to revolutionize healthcare also raises profound questions about long-term safety, permanent biological alterations, and unforeseen medical consequences.
Gene therapy is no longer a distant theoretical concept; it is already being actively deployed to treat certain severe and life-threatening illnesses. These advanced therapeutic interventions are capable of introducing functional copies of faulty genes into a patient’s cells, silencing harmful genetic activity that drives disease, or making precise, direct modifications to the underlying DNA structure. Unlike conventional pharmaceutical medications that must be taken repeatedly—often daily over the course of a lifetime—some cutting-edge genetic treatments are purposefully engineered to work effectively after just one administration.
The medical landscape for genetic interventions has expanded dramatically in recent years. More than 6,000 rare genetic disorders have now been formally identified by the scientific community, although only a small proportion of these conditions currently feature clear biological targets that can be safely and effectively treated. Despite these limitations, gene therapies have already achieved remarkable clinical successes against devastating conditions such as spinal muscular atrophy and sickle cell disease, offering renewed hope to patients who previously faced severely restricted life expectancies and poor quality of life.
Now, emboldened by these early victories, researchers are exploring whether similar genetic approaches could eventually help prevent or manage far more widespread health problems that affect hundreds of millions of people globally. These include high cholesterol, cardiovascular disease, obesity, and type 2 diabetes.
This ambitious pivot raises a fundamental and deeply philosophical question for modern medicine: Just because scientists possess the technological capability to permanently alter a person’s genetic activity, does that automatically mean they should do so?
In a perspective piece published in JAMA Internal Medicine, University of Michigan Health Frankel Cardiovascular Center cardiologists Eric D. Smith, M.D., and Venkatesh L. Murthy, M.D., Ph.D., outline how practicing physicians and biomedical researchers must carefully weigh the immense potential benefits of genomic therapies against their very real, sometimes irreversible risks. The two physician-researchers explain why these advanced treatments represent such a promising paradigm shift, what fundamentally distinguishes them from conventional medicines, and what rigorous milestones must be achieved before they can be safely and ethically offered to millions of healthy or chronically ill people.
Why One-Time Gene Therapy Is Different From Daily Medication
One of the most commercially and clinically appealing features of gene therapy is the enticing possibility of achieving lasting medical results without the burden of repeated treatments or lifelong adherence to complicated medication schedules.
Traditional medicines generally work only as long as patients continue taking them; once a pill is stopped, its chemical presence and therapeutic effects fade from the body. Genomic therapies operate on an entirely different biological level because they act directly on the body’s fundamental genetic material. By providing a healthy version of a gene, suppressing a rogue gene responsible for destructive physiological effects, or modifying a specific DNA sequence, these therapies rewrite the body’s internal instructions.
This unique mechanism makes it scientifically possible to develop treatments intended to work permanently after a single dose. Within the medical and biotechnology sectors, such interventions are frequently referred to as "one-and-done" treatments.
However, medical experts emphasize that receiving a treatment only once does not automatically guarantee that its clinical effects will last a lifetime, nor does it mean the procedure is entirely free from biological limitations.
Dr. Smith explains that many current gene therapies rely on modified, harmless viruses to serve as biological delivery vehicles, carrying therapeutic genetic instructions directly into the target cells of a patient. Because these delivery vehicles are derived from viral structures, the human immune system can naturally recognize them as foreign invaders and develop a potent immunological response against them. As a consequence, administering the exact same genetic treatment a second time may prove exceptionally difficult or clinically impossible, even if the therapeutic benefits of the initial dose begin to wane or fade over time.
Another critical distinction concerns the specific types of cells that are modified during the procedure. Current clinical gene therapies generally target somatic cells, which comprise the vast majority of the body’s cells other than those directly involved in reproduction. Unlike theoretical germline editing, these therapeutic somatic treatments are strictly designed so that their genetic modifications cannot be inherited by future generations, drawing a firm ethical line in current clinical applications.
Why Gene Editing Common Diseases Raises New Risks
For individuals living with rare, highly destructive genetic conditions, the calculation of risk versus reward is often straightforward. The potential benefits of gene therapy may clearly and overwhelmingly outweigh the potential dangers because these patients frequently have few, if any, effective conventional treatment options available, making even an experimental intervention well worth considering.
However, the clinical situation becomes considerably more complicated when this same powerful technology is aimed at common, highly prevalent chronic diseases.
Conditions such as high cholesterol, chronic heart disease, obesity, and diabetes are already managed with well-established, highly studied conventional treatments. Many of these traditional pharmaceutical medications offer a high degree of clinical flexibility: they can be easily adjusted in dosage as a patient’s underlying condition changes over time, or they can be discontinued immediately if troublesome, unexpected side effects develop.
A permanent genetic intervention, by its very nature, may not offer that same vital clinical flexibility.
Dr. Murthy points to another major structural concern involving the sheer scale of the patient population that might eventually receive these treatments. If a serious, unforeseen side effect occurs only rarely within a treated population, it could still ultimately harm a substantial number of individual patients if a preventative or therapeutic gene therapy is administered to millions of people worldwide.
For that precise reason, genomic treatments intended for widespread, mainstream use must meet exceptionally demanding safety standards that far exceed those required for rare disease treatments.
The Problem of Tracking Risks That Could Emerge Years Later
To help determine when genomic therapy is clinically appropriate, Smith and Murthy propose evaluating a series of essential factors, keeping a sharp focus on the long-term realities of patient follow-up. The final phases of evaluation present particularly formidable challenges for the medical community.
Standard clinical trials typically involve relatively small groups of carefully selected patients who are monitored closely for limited, predefined periods of time. Although these initial studies are crucial for identifying many important safety concerns and immediate adverse reactions, they may entirely miss extremely rare complications or complex physiological problems that take years, or even decades, to fully develop in a broader population.
Some adverse biological effects might only become apparent after a complex genetic treatment has successfully reached a much larger, more diverse population outside the controlled environment of a clinical trial.
Dr. Smith argues that long-term monitoring cannot simply be treated as an afterthought or a secondary administrative task. Instead, it needs to be integrated as an essential, foundational part of how gene therapies are formally introduced into everyday medical practice.
Patient registries, which systematically collect standardized health information about individuals receiving particular specialized treatments, have already demonstrated how valuable extended follow-up can be in modern medicine. However, therapies that could eventually scale up to reach millions of everyday patients will require sophisticated monitoring systems capable of operating on a vastly larger, more comprehensive scale.
These monitoring systems must be independent, rigorous, and standardized so that researchers and regulatory agencies can consistently evaluate whether treatments remain genuinely effective over decades and whether unexpected health problems begin to appear over time. Without reliable, long-term data tracking, practicing physicians may struggle to fully comprehend or manage the long-term consequences of permanent genetic interventions that cannot easily be reversed.
Could Some Genetic Changes Be Too Risky to Make Permanent?
Another pressing concern within the medical community is whether certain human diseases or delicate biological processes are suitable for permanent, irreversible treatment at all.
Dr. Murthy emphasizes that merely developing the technological capability to alter a specific genetic target does not automatically make doing so the best or safest medical decision for a patient.
Some chronic medical conditions require careful, continuous adjustments to medication doses over time to match the fluctuating needs of the human body. In other physiological cases, the delicate margin between an effective therapeutic treatment and a harmful one can be extremely narrow. Altering a complex biological process either too much or too little could inadvertently create serious, cascading medical complications.
Conventional pharmaceutical medications offer an important, built-in advantage in these complex clinical situations because physicians retain the continuous ability to modify, reduce, or completely stop treatment whenever necessary. Permanent gene therapies generally lack that safety net.
While scientists may eventually overcome this significant limitation by developing advanced genetic treatments equipped with built-in biological "off-switches" or other precise methods for reversing their effects, those technologies are still largely in developmental phases. Until those reversible approaches have been shown to work reliably and safely in human clinical settings, the inherent ability to undo or adjust a treatment remains a vital safety advantage of traditional medicine.
The Million-Dollar Challenge Facing Gene Therapy
Safety concerns are not the only formidable barrier standing in the way of bringing advanced gene editing into mainstream, everyday healthcare. The question of cost could ultimately determine whether these breakthrough treatments become widely accessible to the general public or remain exclusive interventions available only to a privileged few.
Some existing gene therapies already carry staggering list prices exceeding $1 million for a single patient treatment, with several specialized therapies costing substantially more.
While such astronomical prices may be considered justifiable by healthcare economists and insurers for certain rare, life-threatening conditions—particularly when alternative treatment options are virtually nonexistent—applying a similar pricing model to chronic diseases affecting millions of people would place enormous, unsustainable financial pressure on global healthcare systems.
Smith and Murthy argue that long-term affordability and equitable patient access must therefore be made central components of the scientific and economic discussion from the very beginning of the development process.
Even a remarkably effective gene therapy could inadvertently create troubling new healthcare inequalities if only a tiny percentage of the patient population could actually afford or obtain it. Researchers, healthcare institutions, and policymakers must carefully consider not just whether these advanced treatments work in a laboratory or clinical trial, but also whether they can be delivered broadly without exacerbating existing socioeconomic and health disparities.
Could One Gene-Editing Treatment Prevent Heart Disease for Decades?
Despite the multitude of scientific, ethical, and economic challenges ahead, the prospect of utilizing gene editing to prevent or manage common chronic diseases is steadily transitioning from science fiction into clinical reality.
Researchers are already actively conducting early-stage clinical studies to investigate whether a single genetic treatment can successfully produce safe, long-lasting reductions in low-density lipoprotein, more commonly known as "bad" cholesterol.
LDL cholesterol is a well-established major contributor to the progressive buildup of fatty deposits and plaque inside human arteries, a pathological process that significantly increases the risk of heart attacks, strokes, and other severe cardiovascular events. Achieving and maintaining lower levels of LDL cholesterol over extended periods is a cornerstone strategy for reducing overall cardiovascular risk in at-risk populations.
If gene editing can safely produce sustained, decades-long reductions in cholesterol without continuous intervention, it could eventually offer an entirely new medical approach to protecting long-term cardiovascular health.
However, promising early clinical results alone will not be enough to justify widespread adoption across the broader population. Before these sophisticated therapies can become routine clinical options for common, manageable conditions, researchers must provide convincing, long-term evidence that their therapeutic benefits last, that their associated risks remain acceptably low over many years, and that their overall costs can be managed responsibly by society. Reliable clinical safeguards and tracking systems will also be essential.
For cardiologists Smith and Murthy, the overarching objective is not to unnecessarily hold back the relentless march of genetic medicine. Rather, it is to ensure that a transformative technology with the power to reshape modern healthcare is introduced carefully, thoughtfully, and responsibly.
As gene therapy moves forward from rare disorders toward widespread conditions affecting millions of everyday people, the central challenge for the medical community will be ensuring that the bright promise of lasting protection does not come at the heavy expense of long-term patient safety.
